Gene Pair Information
Gene Pair: TIPARP, PARP1
Related Sentences
| # | PMID | Sentence |
| 1 | 33637776 | BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression. |
| 2 | 33637776 | Poly (ADP-ribose) polymerase (PARP) inhibitors offer a significant clinical benefit for triple-negative breast cancers (TNBCs) with BRCA1/2 mutation. |
| 3 | 33637776 | Phosphoinositide 3-kinase (PI3K) inhibition sensitizes BRCA-proficient TNBC to PARP inhibition, which broadens the indication of PARP inhibitors. |
| 4 | 33637776 | Previously researches have reported that PI3K inhibition induced the defect of homologous recombination (HR) mediated repair by downregulating the expression of BRCA1/2 and Rad51. |
| 5 | 33637776 | Herein, we focused on DNA damage, DNA single-strand breaks (SSBs) repair and DNA double-strand breaks (DSBs) repair three aspects to investigate the mechanism of dual PI3K and PARP inhibition in DNA damage response. |
| 6 | 33637776 | We found that dual PI3K and PARP inhibition with BKM120 and olaparib significantly reduced the proliferation of BRCA-proficient TNBC cell lines MDA-MB-231 and MDA231-LM2. |
| 7 | 33637776 | Olaparib resulted in concomitant gain of PARP1, forkhead box M1 (FOXM1) and Exonuclease 1 (Exo1) while inhibited the activity of PARP. |
| 8 | 33637776 | BKM120 downregulated the expression of PARP1 and PARP2 to assist olaparib in blocking PARP mediated repair of DNA SSBs. |
| 9 | 33637776 | Meanwhile, BKM120 inhibited the expression of BRAC1/2 and Rad51/52 to block HR mediated repair through the PI3K/Akt/NFκB/c-Myc signaling pathway and PI3K/Akt/ FOXM1/Exo1 signaling pathway. |
| 10 | 33637776 | FOXM1 and Exo1 are novel therapeutic targets that serves important roles in DNA damage response. |
| 11 | 34813314 | Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. |
| 12 | 34813314 | Targeting poly(ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation. |
| 13 | 34813314 | Inducing the deficiency of homologous recombination (HR) repair is an effective way to broaden the indication of PARP1/2 inhibitor for more patients with pancreatic cancer. |
| 14 | 34813314 | Bromodomain-containing protein 4 (BRD4) repression has been reported to elevate HR deficiency. |
| 15 | 34813314 | Therefore, we designed, synthetized, and optimized a dual PARP/BRD4 inhibitor <b>III</b>-<b>16</b>, with a completely new structure and high selectivity against PARP1/2 and BRD4. |
| 16 | 34813314 | The advantages of <b>III</b>-<b>16</b> over Olaparib suggest that dual PARP/BRD4 inhibitors are novel and promising agents for the treatment of advanced pancreatic cancer. |
| 17 | 35293552 | The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1. |
| 18 | 35293552 | The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively). |
| 19 | 35293552 | The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98). |
| 20 | 35293552 | The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients. |